Managing the Morbidity Associated with Respiratory Viral Infections in Children with Congenital Heart Disease

Table 3

Palivizumab prophylaxis in children with CHD and its impact on RSV hospitalization rate.

Author (reference)	Location	Methodology	Hospitalization rate without prophylaxis	Hospitalization rate with prophylaxis	Relative reduction
Feltes et al. [9]	International	Randomized, double-blind, placebo-controlled	9.7%	5.3%	45.4%*
Cohen et al. [37]	USA	Prospective, observational	N/A	1.9%	N/A
Chang and Chen [38]	California, USA	Observational	0.56%	0.46%	17.9%
Saji et al. [39]	Japan	Questionnaire	N/A	4.6%	N/A
Saji et al. [40]	Japan	Questionnaire	4.42%	2.53%	42.8%

*denotes statistical significance.